Fair Value Measurements - Additional Information (Detail) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
	Nov. 14, 2017	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Impairment of equity investment		$ 0	$ 27,500	$ 0	$ 27,821
Other income (expense), net		11,810	(12,332)	32,631	17,309
Debt instrument, face amount		1,285,476		1,285,476
Fair value of contingent consideration liability		800	2,000	9,300	1,200
2024 Convertible Notes [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt instrument, maturity date	Nov. 15, 2024
Debt instrument, face amount	$ 570,000	91,640		$ 91,640		$ 105,847
2024 Convertible Notes [Member] | Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt instrument, maturity date				Nov. 15, 2024
Debt instrument, face amount		570,000		$ 570,000
Two Thousand Seventeen Capped Call Transactions [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other income (expense), net				700
Lacerta Therapeutics Inc [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Impairment Loss		$ 0	$ 27,500	$ 0	$ 27,500